Lanreotide medicine supply for 2027
Masarykův onkologický ústav is tendering for a 2027 supply of a lanreotide medicine under reference MOU 581 806. The open, above-threshold procedure has one lot. Estimated value is CZK 12 million excluding VAT; the notice separately states a procurement estimate of CZK 18 million excluding VAT including estimated reserved changes. Quantities are approximate and may vary by up to 50% either way. The base period is 1 January to 31 December 2027, with one possible three-month extension if no successor supply contract can be concluded. The sole award criterion is lowest offer price excluding VAT, assessed by electronic auction. Electronic bids in Czech are required. TED gives a deadline of 9 November 2026 at 10:00 +01:00, later than the timestamp of 8 November at 23:00 UTC. The product specification and contract annexes were not opened.
Estimated value CZK12m ex VAT; separate procurement estimate CZK18m ex VAT includes estimated reserved changes.
TED (Tenders Electronic Daily), Official Journal of the European Union
Overview
Masarykův onkologický ústav is tendering for a 2027 supply of a lanreotide medicine under reference MOU 581 806. The open, above-threshold procedure has one lot. Estimated value is CZK 12 million excluding VAT; the notice separately states a procurement estimate of CZK 18 million excluding VAT including estimated reserved changes. Quantities are approximate and may vary by up to 50% either way. The base period is 1 January to 31 December 2027, with one possible three-month extension if no successor supply contract can be concluded. The sole award criterion is lowest offer price excluding VAT, assessed by electronic auction. Electronic bids in Czech are required. TED gives a deadline of 9 November 2026 at 10:00 +01:00, later than the timestamp of 8 November at 23:00 UTC. The product specification and contract annexes were not opened.
Information based on the public notice
Ask about this tender
What the buyer needs
Supply of a lanreotide medicinal product under one lot for 2027, with one conditional three-month extension and quantity variation of up to ±50%.
- Electronic submission in Czech is required; e-catalogues are not allowed. Electronic invoicing, ordering and payment are provided for in the notice. The lowest-price criterion is evaluated through an electronic auction.
Lots
LOT-0001 ·Lanreotid [2027]
Tender details
- Buyer
- Masarykův onkologický ústav
- Country
Czechia
- Procedure
- open
- Classification
- Lanreotide medicine · CPV 33600000
- Notice reference
- 693666-2026
- Authority and reference
- Masarykův onkologický ústav; MOU 581 806.
- Estimated value
- CZK 12,000,000 excluding VAT.
- Value including reserved changes
- CZK 18,000,000 excluding VAT including estimated reserved changes; not an award or stated ceiling.
- Product and lot
- Lanreotide medicinal product; one lot.
- Quantity flexibility
- Approximate amount; buyer may order up to 50% more or 50% less.
- Term and option
- 1 January–31 December 2027; one possible three-month extension if no replacement supply contract can be concluded.
- Award criterion
- Lowest price excluding VAT, weighted 100%; electronic auction.
- Submission terms
- Electronic submission in Czech required; no e-catalogue; electronic invoicing required.
- Deadline
- 9 November 2026 at 10:00 +01:00; timestamp differs.
What to check in the tender documents
- The medicine specification, package sizes/strengths and exact quantities are set out in referenced procurement annexes that were not opened. No award is reported.
Original notice
Read the original description
Lanreotid [2027]
Official source: TED (Tenders Electronic Daily), Official Journal of the European Union ↗
https://ted.europa.eu/en/notice/-/detail/693666-2026
Source retrieved: 2026-10-12T22:23:05.990568Z